DNA Testing Is a Slippery Slope
By Russell Saunders,
The Daily Beast
| 04. 14. 2015
Untitled Document
Let’s say you have a whole lot of money.
Let’s say you have so much money that, even after you’ve purchased a basketball team and a chain of movie theaters, you still have enough cash left over to invest in a maverick approach to your own health care. Should you sink an unspecified sum into ordering every test you can find in the off chance that sooner or later you’re going to detect something valuable?
Mark Cuban says “yes.”
In a series of tweets posted at the beginning of this month, the media baron and basketball franchisee admonished his followers that, if they were sufficiently affluent, they should order blood tests for “everything available” on a quarterly basis in order to establish a baseline for their own health. In the event of some deviation from the any given person’s aggregate normal values, it might detect some abnormality earlier than it would otherwise be found when it started creating symptoms.
Looking at Cuban’s page now, it seems the tweets in question from April 1 have gone missing. But...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Katrina Miller, The New York TImes | 02.05.2026
Joseph Yracheta: The Native Biodata Consortium is the first nonprofit data and sample repository within the geographic bounds and legal jurisdiction of an American Indian nation, on the Cheyenne River Sioux Reservation in Eagle Butte, S.D.
NativeBio participated in a ...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...